Cell-Cycle Position of Single MYC-Driven Cancer Cells Dictates Their Susceptibility to a Chemotherapeutic Drug
Overview
Cell Biology
Molecular Biology
Authors
Affiliations
While many tumors initially respond to chemotherapy, regrowth of surviving cells compromises treatment efficacy in the long term. The cell-biological basis of this regrowth is not understood. Here, we characterize the response of individual, patient-derived neuroblastoma cells driven by the prominent oncogene MYC to the first-line chemotherapy, doxorubicin. Combining live-cell imaging, cell-cycle-resolved transcriptomics, and mathematical modeling, we demonstrate that a cell's treatment response is dictated by its expression level of MYC and its cell-cycle position prior to treatment. All low-MYC cells enter therapy-induced senescence. High-MYC cells, by contrast, disable their cell-cycle checkpoints, forcing renewed proliferation despite treatment-induced DNA damage. After treatment, the viability of high-MYC cells depends on their cell-cycle position during treatment: newborn cells promptly halt in G phase, repair DNA damage, and form re-growing clones; all other cells show protracted DNA repair and ultimately die. These findings demonstrate that fast-proliferating tumor cells may resist cytotoxic treatment non-genetically, by arresting within a favorable window of the cell cycle.
Towards understanding cancer dormancy over strategic hitching up mechanisms to technologies.
Yang S, Seo J, Choi J, Kim S, Kuk Y, Park K Mol Cancer. 2025; 24(1):47.
PMID: 39953555 PMC: 11829473. DOI: 10.1186/s12943-025-02250-9.
Targeting therapy-persistent residual disease.
Sun X, Wu L, Altschuler S, Hata A Nat Cancer. 2024; 5(9):1298-1304.
PMID: 39289594 DOI: 10.1038/s43018-024-00819-9.
A MYCN-driven de-differentiation profile identifies a subgroup of aggressive retinoblastoma.
Ryl T, Afanasyeva E, Hartmann T, Schwermer M, Schneider M, Schroder C Commun Biol. 2024; 7(1):919.
PMID: 39079981 PMC: 11289481. DOI: 10.1038/s42003-024-06596-6.
Saldana-Guerrero I, Montano-Gutierrez L, Boswell K, Hafemeister C, Poon E, Shaw L Nat Commun. 2024; 15(1):3745.
PMID: 38702304 PMC: 11068915. DOI: 10.1038/s41467-024-47945-7.
Cancer cell cycle heterogeneity as a critical determinant of therapeutic resistance.
Maleki E, Bahrami A, Matin M Genes Dis. 2023; 11(1):189-204.
PMID: 37588236 PMC: 10425754. DOI: 10.1016/j.gendis.2022.11.025.